课题基金 / 基金详情

项目摘要

项目成果

M M GOTTESMAN的其他基金

相似基金

相关文献

中文摘要
翻译
组织蛋白酶原L(也称为MEP,代表主要排泄蛋白质)是一种 溶酶体蛋白酶,其由蛋白酶合成并大量分泌, 恶性转化的小鼠和人类细胞,以及正常细胞 肾脏和肝脏 组织蛋白酶L是一种半胱氨酸酸性蛋白酶, 广泛的底物特异性,包括许多细胞外基质 印刷受体. 为了了解组织蛋白酶L的调节模式,我们 分离出小鼠和人类的基因并研究它们的上游, 启动子区。 小鼠启动子具有位于启动子5'和3'端的元件。 影响肿瘤调控的转录起始位点 启动子,TPA。 人类基因,定位于9号染色体,似乎 具有两个不同的启动子,其决定两种转录物的表达 在大多数人体组织中。 一个全长人类基因的缺失分析 在培养的小鼠细胞中表达的组织蛋白酶原L cDNA揭示了许多 参与亚细胞定位的蛋白质的特征, 功能 蛋白质氨基末端的序列 参与蛋白质折叠,它们的缺失导致捕获 在内质网中的表达。 氨基酸残基 组织蛋白酶L羧基末端影响其被 秘密的
英文摘要
Procathepsin L (also known as MEP, for major excreted protein) is a lysosomal protease which is synthesized and secreted in large amounts by malignantly transformed mouse and human cells, as well as by normal cells of the kidney and liver. Cathepsin L is a cysteine acid protease with a broad substrate specificity which includes many extracellular matrix substrates. To understand the mode of regulation of cathepsin L, we have isolated both the mouse and human genes and studied their upstream, promoter regions. The mouse promoter has elements both 5' and 3' to the start site of transcription which affect regulation by the tumor promoter, TPA. The human gene, which maps to chromosome 9, appears to have two distinct promoters which determine expression of two transcripts in most human tissues. A deletion analysis of a full-length human procathepsin L cDNA expressed in cultured mouse cells has revealed many features of the protein involved in subcellular localization and function. Sequences in the amino terminal section of the protein appear to be involved in protein folding and their deletion results in trapping of procathepsin L in the endoplasmic reticulum. Amino acid residues at the carboxy terminal end of cathepsin L affect its ability to be secreted.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GENETIC ANALYSIS OF THE MULTIPLE DRUG RESISTANCE PHENOTYPE IN TUMOR CELLS
CONTROL OF SYNTHESIS OF A TRANSFORMATION-DEPENDENT SECRETED GLYCOPROTEIN
SYNTHESIS AND FUNCTION OF A TRANSFORMATION-DEPENDENT SECRETED LYSOSOMAL PROTEASE
GENETIC ANALYSIS OF THE MULTIPLE DRUG RESISTANCE PHENOTYPE IN TUMOR CELLS
海外基金